2017
From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection
Kudalkar SN, Beloor J, Quijano E, Spasov KA, Lee WG, Cisneros JA, Saltzman WM, Kumar P, Jorgensen WL, Anderson KS. From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 115: e802-e811. PMID: 29279368, PMCID: PMC5789948, DOI: 10.1073/pnas.1717932115.Peer-Reviewed Original ResearchConceptsHIV-1 drugsDrug-resistant HIV-1 strainsHIV-1 drug-resistant strainsPreclinical candidateDrug-resistant HIV-1HIV-1-infected T cellsDaily treatment regimensActive antiretroviral therapyT cell lossSynergistic antiviral activityHIV-1 infectionAnti-HIV-1 agentsCombination drug regimensHIV-1 strainsMajor therapeutic challengeHIV-1 pandemicPlasma drug concentrationsDrug-resistant strainsVivo pharmacokinetic behaviorAntiretroviral therapyDrug regimensTherapeutic challengeViral loadTreatment regimensSingle dose
2008
T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice
Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, Laouar A, Yao J, Haridas V, Habiro K, Yang YG, Jeong JH, Lee KY, Kim YH, Kim SW, Peipp M, Fey GH, Manjunath N, Shultz LD, Lee SK, Shankar P. T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice. Cell 2008, 134: 577-586. PMID: 18691745, PMCID: PMC2943428, DOI: 10.1016/j.cell.2008.06.034.Peer-Reviewed Original ResearchConceptsHIV infectionAntiviral siRNAsT cellsAnimal modelsCD4 T-cell countCD4 T-cell lossPeripheral blood mononuclear cellsSuppress HIV-1 infectionHu-HSC miceHu-PBL miceT-cell countsT cell lossHIV-1 infectionBlood mononuclear cellsNaive T cellsPreclinical animal modelsSuitable animal modelHumanized miceInfected miceMononuclear cellsSuppress viremiaCell countCell lossTherapeutic potentialHematopoietic stem cells